Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A PHASE II / III STUDY OF TREATMENT WITH MK-0646 IN COMBINATION WITH CETUXIMAB AND IRINOTECAN FOR PATIENTS WITH METASTASIC COLORECTAL CANCER

ABSTRACT: Interventions: Group name:Arm A Type of group;1 N° of participants:370 Intervention(s) description:Patients will be given an infusion of 10 mg / kg of MK-0646 for 60 minutes. Group name:Arm C Type of group;2 N° of participants:370 Intervention(s) description:The MK-0646 will be replaced by saline. This saline placebo will be referred to hereinafter as placebo Primary outcome(s): Outcome name:defined as the time from randomization to death due to any cause. Patients without, death documented at the time of the final analysis will be counted on the date of the last follow-up. Measure:General survival Timepoints:until the date of the last follow-up. ; Outcome name:defined as the time from randomization to the first documented evolution of the disease, as documented by an independent central laboratory, or death due to any cause, whichever occurs first. Measure:Survival without evolution Timepoints:to the first documented evolution of the disease, as documented by an independent central laboratory, or death due to any cause, whichever occurs first. Study Design: This is a multicenter, double-blind, randomized, Phase II / III study of MK-0646 administered to patients with metastatic colorectal cancer who previously failed both chemotherapies based on oxaliplatin and irinotecan.

DISEASE(S): Malignant Neoplasm Of Colon

PROVIDER: 2563482 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer

Project description:Main objective :To estimate the 6-month (24 weeks) progression-free survival for patients with metastatic CRC who are treated with enzastaurin. Primary endpoints: Progression Free survival estimate at 6 months is the primary efficacy endpoint. Progression-free survival is defined as the time from the date of the first enzastaurin dose to the first date of documented progressive disease or death due to any cause, whichever occurs first. Progression-free survival will be censored at the date of the last assessment visit for patients who are still alive and who have not had documented progressive disease.

| 2516768 | ecrin-mdr-crc

Intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with RAS/B-RAF wild-type metastatic colorectal cancer: a randomized phase 2 trial

Project description:Primary objectives: To investigate whether experimental intermittent treatment of Panitumumab + FOLFIRI (given until progression during treatment or cumulative toxicity) results in a Progression Free Survival on treatment (PFSOT) similar to that obtained with standard continuous treatment of Panitumumab + FOLFIRI (given until progression or cumulative toxicity). Primary endpoints: PFSot is defined as the time from randomization to the firstobjective disease progression documented in patients undergoing treatment cycle (objective disease progression during treatment free intervals are excluded) or death due to any cause, whichever occurs first.

| 2537370 | ecrin-mdr-crc

Project description:cause of death

| PRJNA904283 | ENA

Phase II study of Panitunumab plus Cetuximab in pretreated in patients with metastatic colorectal cancer

Project description:Primary objectives: Assess the efficacy of panitumumab in combination with Trifluridine- Tipiracile vs standard third line therapy (Trifluridine-Tipiracile) as measured by PFS Primary endpoints: PFS: defined as the time from randomization to the earliest documented disease progression or death due to any cause

| 2538100 | ecrin-mdr-crc

Project description:Release on specified date or upon publication, whichever is first

| PRJNA550427 | ENA

A phase 2 study of temozolomide in patients affected by metastatic colonrectal cancer with hypermethylation of 06-methylguanine-dna-methyltransferase

Project description:Primary objectives: - To assess the activity (in terms of response rate according to RECIST 1.1 criteria) of temozolomide (TMZ) in patients with refractory metastatic colorectal cancer with hypermethylation of MGMT Primary endpoints: - Objective tumor response rate according to RECIST 1.1 criteria - Duration of response, as the time period from first documentation of response (complete or partial response) to the date of first occurrence of documented disease progression - Progression-free survival, defined as the time period from start of the treatment to the date of first occurrence of documented disease progression or death from any cause within 60 days from the last disease assessment or from cycle 1, day 1 - Overall survival, defined as the time period from enrollment to death from any cause.

| 2531067 | ecrin-mdr-crc

Biopsies from advanced melanoma before and/or after treatment with nivolumab

Project description:Expression profiling of tumor samples obtained during CA209-038 (ClinicalTrials.gov Identifier: NCT01621490). The purpose of this study is to evaluate pharmacodynamic changes of nivolumab and nivolumab in combination with ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced). Samples are rumor core needle biopsies obtained at trial enrolment (i.e. Screen) and/or at Cycle 1 Day 29 (i.e.Week 4) from Subjects With Advanced Melanoma (Unresectable or Metastatic) treated with nivolumab (BMS-936558,MDX-1106) 3 mg/kg solution intravenously every 2 weeks on Bristol-Myers Squibb clinical trial protocol CA209-038 Part 1 . Cohort 2 patients have progressed on anti-CTLA4 (ipilimumab) monoclonal antibody therapy. Values are from an interim lock of the trial data in July 2014. Best overall response (BOR) was defined using RECIST 1.1 criteria: tumor assessments between date of first dose and the date of first objectively documented progression, or the date of non-missing subsequent anti-cancer therapy (whichever occurs first) were used to derive BOR. MPCT is Maximum reduction in tumor size (index lesions only) up to first progression, and is the value typically shown on a waterfall plot.

2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Project description:Primary objectives: • to gather preliminary evidence of superior activity, of RO5083945 added to FOLFIRI versus FOLFIRI + cetuximab in terms of progression free survival (PFS) in patients with KRAS WT colorectal cancer • to gather preliminary evidence of superior activity, of RO5083945 added to FOLFIRI versus FOLFIRI alone in terms of progression free survival (PFS) in patients with KRAS mutant colorectal cancer Primary endpoints: The primary variable is PFS defined as the time between randomization and date of first documented disease progression or death, whichever occurs first.

| 2528754 | ecrin-mdr-crc

[E-MTAB-610] Tag profiling of genes from two Pachycladon species

Project description:Tag profiling and expression analysis of genes from Pachycladon enysii and Pachycladon fastigiatum. ArrayExpress Release Date: 2011-06-01 Publication Title: Short read expression profiling in a non-model allopolyploid plant Publication Author List: Voelckel, C, Gruenheit, N, Biggs, P, Deusch, O, Lockhart, PJ Person Roles: submitter Person Last Name: Voelckel Person First Name: Claudia Person Mid Initials: Person Email: c.voelckel@massey.ac.nz Person Phone: Person Address: Institute of Molecular Biosciences, Private Bag 11 222, Palmerston North 4442 Person Affiliation: Institute of Molecular Biosciences, Allan Wilson Centre for Molecular Ecology and Evolution

2011-07-14 | GSE30618 | GEO

Integrated bioinformatic and wet-lab approach to identify potential oncogenic networks in neuroblastoma: MEIS1

Project description:The pediatric tumor neuroblastoma is the second cause of cancer-related death in children. Although several recurrent gene aberrations have been found, the main signaling networks in the neuroblastoma cell, that can give important clues for more specific, more efficient treatment, is still unknown. Here we demonstrate an analysis of the MEIS1 pathway in neuroblastic tumors. It suggests important regulatory connections to tumor differentiation, cell cycle, and cell death. Time-course experiment of MEIS1-shRNA induction, with 5 timepoints.

2012-09-24 | E-GEOD-17827 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data